IP Library › Patent Application 19391108
Patent Application
App. No. 19/391,108

ANALYTICAL METHOD FOR CHARACTERIZATION OF RNA IN LIPID NANOPARTICLES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/391,108
Abstract

Disclosed herein are methods for analyzing a nucleic acid encapsulated in a lipid nanoparticle (LNP). In one aspect, the methods may comprise solubilizing an LNP with a nonionic surfactant to form an analyte sample, introducing the analyte sample into a capillary, and detecting the nucleic acid via capillary electrophoresis (CE). In certain aspects, the nonionic surfactant may comprise from about 1% to about 10% v/v of the analyte sample.

Claims (24)

1 . A method for analyzing a nucleic acid encapsulated in a delivery vehicle, comprising

a. solubilizing said delivery vehicle with a nonionic surfactant to form an analyte sample, said nonionic surfactant comprising from about 1% to about 10% v/v of said analyte sample;

b. introducing said analyte sample into a capillary; and

c. detecting said nucleic acid via capillary electrophoresis (CE).

2 . The method of claim 1 , wherein said nucleic acid is selected from a single stranded (ssRNA), a double stranded RNA (dsRNA), a viral RNA, a retroviral RNA replicon RNA, a small interfering RNA (siRNA), an antisense RNA (asRNA), a circular RNA (circRNA), a ribozyme, an aptamer, a riboswitche, an immunostimulating/immunostimulatory RNA, a transfer RNA (tRNA), a ribosomal RNA (rRNA), a small nuclear RNA (snRNA), a small nucleolar RNA (snoRNA), a microRNA (miRNA), a Piwi-interacting RNA (piRNA), and combinations thereof.

3 . The method of claim 1 , wherein said nucleic acid is mRNA.

4 . The method of claim 1 , wherein said nucleic acid comprises at least one, or at least two, or at least three, or at least four, or at least five nucleic acid species.

5 . The method of claim 1 , wherein said nucleic acid comprises more than five nucleic acid species.

6 . The method of claim 1 , wherein said nucleic acid is from about 1000 to about 10,000 kb, or from about 2000 kb to about 8000 kb, or from about 4000 kb to about 6000 kb.

7 . The method of claim 1 , wherein said nucleic acid is present in said analyte sample in an amount of from about 1 to about 25 μg, or from about 2 to about 20 μg, or from about 3 to about 15 μg, or from about 4 to about 10 μg or from about 5 to about 12 μg.

8 . The method of claim 1 , wherein said nonionic surfactant is present at a concentration of from about 1% to about 8%, or from about 4% to about 6%.

9 . The method of claim 1 , wherein said nonionic surfactant is Triton X-100.

10 . The method of claim 1 , wherein said delivery vehicle is a peptoid-based.

11 . The method of claim 1 , wherein said delivery vehicle is a lipid nanoparticle (LNP).

12 . The method of claim 1 , wherein said delivery vehicle comprises a hydroxyethyl-capped tertiary amino lipidated cationic peptoid.

13 . The method of claim 1 , wherein said delivery vehicle comprises an anionic/zwitterionic component.

14 . The method of claim 1 , wherein said delivery vehicle comprises a PEGylated lipid.

15 . The method of claim 1 , wherein said delivery vehicle comprises a neutral lipid component.

16 . The method of claim 1 , wherein said delivery vehicle comprises a sterol.

17 . The method of claim 1 , wherein said delivery vehicle comprises a shielding component.

18 . The method of claim 1 , wherein said delivery vehicle comprises DLin-MC3-DMA.

19 . The method of claim 1 , wherein said delivery vehicle comprises SM-102.

20 . The method of claim 1 , wherein said analyte sample further comprises formamide.

21 - 30 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2026
From: NUTCRACKER THERAPEUTICS, INC.
To: MEDICI THERAPEUTICS, INC.
Reel/Frame 074407/0403 →